Education
About Us
Working with TipRanks
Follow Us
Azenta (AZTA)
NASDAQ:AZTA
AZTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.91 - $55.64
Previous CloseN/A
Volume88.55K
Average Volume (3M)677.42K
Market Cap
$1.34B
Enterprise Value$1.14B
Total Cash (Recent Filing)$318.86M
Total Debt (Recent Filing)$52.63M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 18, 2025EPS Estimate
0.19Last Dividend Ex-Date
Dec 02, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding45,839,730
10 Day Avg. Volume900,568
30 Day Avg. Volume677,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda31.49
Forecast
1Y Price Target
$33.67Price Target Upside4.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Margin ImprovementAzenta is expected to achieve margin improvement, which should justify a higher valuation.
Strategic PartnershipsA new partnership in cell and gene therapy expands Azenta's business portfolio and enhances growth opportunities.
Bears Say
Geopolitical RisksChina is expected to remain a double-edged sword that could keep Azenta at a higher risk of exposure if geopolitical tensions continue.
Order DelaysThe recent quarterly results were affected by order delays and missed expectations in certain segments.
Azenta News
AZTA FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest stock price was $23.91 and its highest was $55.63 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.34B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 18, 2025 which is in 94 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 05, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.136 by $0.054.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.19.
How many shares outstanding does Azenta have?
Azenta has 45,839,730 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.19 in its last earnings report, beating expectations of $0.136. Following the earnings report the stock price went down -17.001%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in AZTA
Azenta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.67 (4.96% Upside)
$33.67 (4.96% Upside)
Hedge Fund Trend
Decreased
By 45.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $69.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.93%
12-Months-Change
Fundamentals
Return on Equity
-1.74%
Trailing 12-Months
Asset Growth
-13.09%
Trailing 12-Months
Company Description
Azenta
Azenta, Inc. (AZTA) is a leading provider of life sciences solutions, focusing on biobanking and laboratory services. The company operates primarily in the biotechnology and pharmaceutical sectors, offering a range of products and services such as sample management, genomic analysis, and data solutions. Azenta's mission is to empower researchers and organizations in the life sciences field by providing innovative solutions that enhance the efficiency and effectiveness of their research processes.
AZTA Company Deck
AZTA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced view with significant achievements in areas like next-generation sequencing and improved financial metrics, countered by challenges in core products revenue and specific segments like Gene Synthesis and Sanger Sequencing. While highlights in financial positions and reaffirmed guidance are positive, the lowlights concerning revenue declines in key areas offset these gains.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$33.67
▲(4.96% Upside)
Technical Analysis
Ownership Overview
11.51% Insiders
34.65% Mutual Funds
0.15% Other Institutional Investors
22.67% Public Companies and
Individual Investors